The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center international trial is to evaluate the safety and
effectiveness of adding iloprost or placebo (an inactive substance that contains no active
study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will
also examine whether patients on sildenafil can reduce the number of iloprost inhalations
from the approved 6 doses per day to 4 doses per day.